Rchr
J-GLOBAL ID：202401014714097160
Update date: Oct. 03, 2024
Kato Motoyasu
カトウ モトヤス | Kato Motoyasu
Affiliation and department：
Research theme for competitive and other funds (2)：
- 2022 - 2025 The Effect of Allicin for Pulmonary Fibrosis
- 2017 - 2022 The basic research of treatment for drug-induced lung injury focusing on epithelial-mesenchymal transition
Papers (48)：
-
Shiting Xu, Takehito Shukuya, Shoko Shimamura, Takuo Hayashi, Yoshihiko Sato, Hitomi Shiozaki, Toshihiko Nishioki, Koichi Nishino, Motoyasu Kato, Aritoshi Hattori, et al. Hyperprogressive disease under anti-PD-1 rechallenge after initial response to anti-PD-1 treatment for non-small cell lung cancer: a case report. Translational lung cancer research. 2024. 13. 3. 666-672
-
Yuichi Nagata, Takayasu Watanabe, Yuki Tanabe, Motoyasu Kato, Takehito Shukuya, Kuniaki Seyama, Kazuhisa Takahashi. Extrapleural air secondary to idiopathic pulmonary fibrosis-related pneumomediastinum. Respirology case reports. 2024. 12. 1. e01271
-
Shun Nakazawa, Motoyasu Kato, Yuriko Terayama, Naho Sakamoto Matubara, Yoshihiko Sato, Ryoko Murashima, Daisuke Hayakawa, Shouichi Okamoto, Kazuhisa Takahashi. Trifluridine and Tipiracil Hydrochloride Combination-Induced Interstitial Pneumonia: A Case Report. International medical case reports journal. 2024. 17. 101-104
-
Masaki Okamoto, Kiminori Fujimoto, Takeshi Johkoh, Atsushi Kawaguchi, Hiroshi Mukae, Noriho Sakamoto, Takashi Ogura, Satoshi Ikeda, Yasuhiro Kondoh, Yasuhiko Yamano, et al. A prospective cohort study of periostin as a serum biomarker in patients with idiopathic pulmonary fibrosis treated with nintedanib. Scientific reports. 2023. 13. 1. 22977-22977
-
Motoyasu Kato, Shinichi Sasaki, Wataru Mori, Makiko Kohmaru, Takashi Akimoto, Eri Hayakawa, Soichiro Soma, Yuta Arai, Naho Sakamoto Matsubara, Shun Nakazawa, et al. Nintedanib administration after the onset of acute exacerbation of interstitial lung disease in the real world. Scientific reports. 2023. 13. 1. 12528-12528
ｍore...
Return to Previous Page
